Check point inhibitors a new era in renal cell carcinoma treatment View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-05-04

AUTHORS

Mohamed Alsharedi, Heather Katz

ABSTRACT

In the United States, the estimated number of new cases of renal cell carcinoma (RCC) is approximately 65,000 case with about 15,000 deaths in the year of 2018 (Siegel et al. in CA Cancer J Clin 68(1):7, 2018). RCC as an immunogenic malignancy is supported by many theories and facts which include tumor richness of lymphocytes infiltrate, the occurrence of spontaneous tumor regression, and the proved effect of traditional immunotherapy (Finke et al. in J Immunother 11(1):1–11, 1992), all these factors support the potential therapeutic effect of the novel immunotherapeutic agents in RCC. Historically, complete tumor regression in metastatic RCC is achievable in a minority of patients through traditional immunotherapies such as high-dose interleukin-2 (IL-2) (Fyfe et al. in J Clin Oncol 13(3):688, 1995) and interferon-alfa (IFNa) (Negrier et al. in N Engl J Med 338(18):1272, 1998); however due to the significant rate of toxicities and low efficacy; accordingly the targeted therapy with tyrosine kinase inhibitors (TKIs) and vascular endothelial growth factor-antibodies (VEGF) became the standard and prevalent treatment approach for advanced RCC both in front and subsequent lines of therapy (Escudier et al. in Ann Oncol. 25(Suppl 3):iii49–iii56, 2014). A new avenue of immunotherapy utilizing novel strategy to block immune checkpoints has emerged in a new era for RCC treatment (Ascierto et al. in J Transl Med 12:291, 2014). Results from clinical trials are encouraging in both front-line and second-line settings, in a phase III trial (CheckMate 025) nivolumab compared to everolimus improved overall survival in previously treated metastatic RCC who had progressed on prior treatment with targeting agents (Motzer et al. in N Engl J Med 373:1803, 2015). CheckMate 214, a phase III trial, demonstrated superior overall survival and objective response with combined checkpoint inhibitors compared to sunitinib in Treatment-Naïve Advanced RCC among intermediate- and poor-risk group (Motzer et al. in N Engl J Med. 378(14):1277–1290, 2018). In this review, we discuss the systemic Immunotherapy with checkpoint inhibitors that have been approved or are currently being investigated in RCC, clinical experience with these agents, and its future development. More... »

PAGES

85

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12032-018-1147-y

DOI

http://dx.doi.org/10.1007/s12032-018-1147-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1103813735

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29728867


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Immunological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "B7-H1 Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ipilimumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nivolumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Programmed Cell Death 1 Receptor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, 1400 Hal Greer Blvd., 25701, Huntington, WV, USA", 
          "id": "http://www.grid.ac/institutes/grid.490061.a", 
          "name": [
            "Department of Hematology/Oncology, Joan C. Edwards School of Medicine Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA", 
            "Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, 1400 Hal Greer Blvd., 25701, Huntington, WV, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Alsharedi", 
        "givenName": "Mohamed", 
        "id": "sg:person.01037220762.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037220762.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology/Oncology, Joan C. Edwards School of Medicine Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA", 
          "id": "http://www.grid.ac/institutes/grid.259676.9", 
          "name": [
            "Department of Hematology/Oncology, Joan C. Edwards School of Medicine Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Katz", 
        "givenName": "Heather", 
        "id": "sg:person.011543016727.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011543016727.10"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/2051-1426-3-s2-p353", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044738460", 
          "https://doi.org/10.1186/2051-1426-3-s2-p353"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12967-014-0291-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008604592", 
          "https://doi.org/10.1186/s12967-014-0291-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-05-04", 
    "datePublishedReg": "2018-05-04", 
    "description": "In the United States, the estimated number of new cases of renal cell carcinoma (RCC) is approximately 65,000 case with about 15,000 deaths in the year of 2018 (Siegel et al. in CA Cancer J Clin 68(1):7, 2018). RCC as an immunogenic malignancy is supported by many theories and facts which include tumor richness of lymphocytes infiltrate, the occurrence of spontaneous tumor regression, and the proved effect of traditional immunotherapy (Finke et al. in J Immunother 11(1):1\u201311, 1992), all these factors support the potential therapeutic effect of the novel immunotherapeutic agents in RCC. Historically, complete tumor regression in metastatic RCC is achievable in a minority of patients through traditional immunotherapies such as high-dose interleukin-2 (IL-2) (Fyfe et al. in J Clin Oncol 13(3):688, 1995) and interferon-alfa (IFNa) (Negrier et al. in N Engl J Med 338(18):1272, 1998); however due to the significant rate of toxicities and low efficacy; accordingly the targeted therapy with tyrosine kinase inhibitors (TKIs) and vascular endothelial growth factor-antibodies (VEGF) became the standard and prevalent treatment approach for advanced RCC both in front and subsequent lines of therapy (Escudier et al. in Ann Oncol. 25(Suppl 3):iii49\u2013iii56, 2014). A new avenue of immunotherapy utilizing novel strategy to block immune checkpoints has emerged in a new era for RCC treatment (Ascierto et al. in J Transl Med 12:291, 2014). Results from clinical trials are encouraging in both front-line and second-line settings, in a phase III trial (CheckMate 025) nivolumab compared to everolimus improved overall survival in previously treated metastatic RCC who had progressed on prior treatment with targeting agents (Motzer et al. in N Engl J Med 373:1803, 2015). CheckMate 214, a phase III trial, demonstrated superior overall survival and objective response with combined checkpoint inhibitors compared to sunitinib in Treatment-Na\u00efve Advanced RCC among intermediate- and poor-risk group (Motzer et al. in N Engl J Med. 378(14):1277\u20131290, 2018). In this review, we discuss the systemic Immunotherapy with checkpoint inhibitors that have been approved or are currently being investigated in RCC, clinical experience with these agents, and its future development.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12032-018-1147-y", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094524", 
        "issn": [
          "1357-0560", 
          "1559-131X"
        ], 
        "name": "Medical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "keywords": [
      "renal cell carcinoma", 
      "metastatic renal cell carcinoma", 
      "advanced renal cell carcinoma", 
      "tyrosine kinase inhibitors", 
      "interferon alfa", 
      "checkpoint inhibitors", 
      "overall survival", 
      "traditional immunotherapy", 
      "tumor regression", 
      "interleukin-2", 
      "high-dose interleukin-2", 
      "renal cell carcinoma treatment", 
      "second-line setting", 
      "improved overall survival", 
      "superior overall survival", 
      "poor-risk group", 
      "phase III trials", 
      "minority of patients", 
      "novel immunotherapeutic agents", 
      "potential therapeutic effects", 
      "spontaneous tumor regression", 
      "complete tumor regression", 
      "prevalent treatment approach", 
      "vascular endothelial growth", 
      "immunogenic malignancies", 
      "CheckMate 214", 
      "systemic immunotherapy", 
      "III trials", 
      "objective response", 
      "immune checkpoints", 
      "immunotherapeutic agents", 
      "cell carcinoma", 
      "targeted therapy", 
      "RCC treatment", 
      "clinical trials", 
      "therapeutic effect", 
      "subsequent lines", 
      "carcinoma treatment", 
      "treatment approaches", 
      "clinical experience", 
      "immunotherapy", 
      "prior treatment", 
      "endothelial growth", 
      "new cases", 
      "proved effect", 
      "kinase inhibitors", 
      "low efficacy", 
      "therapy", 
      "treatment", 
      "inhibitors", 
      "trials", 
      "survival", 
      "significant rate", 
      "agents", 
      "novel strategy", 
      "nivolumab", 
      "patients", 
      "carcinoma", 
      "malignancy", 
      "regression", 
      "lymphocytes", 
      "death", 
      "efficacy", 
      "United States", 
      "new era", 
      "cases", 
      "toxicity", 
      "effect", 
      "review", 
      "group", 
      "years", 
      "setting", 
      "new avenues", 
      "response", 
      "factors", 
      "minority", 
      "occurrence", 
      "checkpoint", 
      "rate", 
      "experience", 
      "future development", 
      "era", 
      "strategies", 
      "development", 
      "lines", 
      "number", 
      "avenues", 
      "results", 
      "growth", 
      "point", 
      "fact", 
      "approach", 
      "state", 
      "theory", 
      "richness"
    ], 
    "name": "Check point inhibitors a new era in renal cell carcinoma treatment", 
    "pagination": "85", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1103813735"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12032-018-1147-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29728867"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12032-018-1147-y", 
      "https://app.dimensions.ai/details/publication/pub.1103813735"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:06", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_781.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12032-018-1147-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12032-018-1147-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12032-018-1147-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12032-018-1147-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12032-018-1147-y'


 

This table displays all metadata directly associated to this object as RDF triples.

219 TRIPLES      21 PREDICATES      133 URIs      123 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12032-018-1147-y schema:about N25bdcb6ab14f42039755574a0a66bbe3
2 N4478bc84beb2477eb93cd799464fa148
3 N5291099b6f434e0cadc0c7b4d0ad0578
4 N5dda0171ce564ad3ab336b67ae8b290e
5 N8604732003da4566a8df0017deb393b0
6 N9ed459eb3b304a93b193a7e87d646a8f
7 Nd85f3d06c8e54f39971bb58bed17b8b1
8 Ne09769bfb4094951bfd8bc619629e9f3
9 Nf5153361926044a9bfd6e0277b20eb4e
10 Nf5bd4872ab8e434493c9e13f808c4ee5
11 Nfedc882152244a63adbd9d9705193206
12 anzsrc-for:11
13 anzsrc-for:1112
14 schema:author N745a8202b60043d6856ca4558ce7d000
15 schema:citation sg:pub.10.1186/2051-1426-3-s2-p353
16 sg:pub.10.1186/s12967-014-0291-1
17 schema:datePublished 2018-05-04
18 schema:datePublishedReg 2018-05-04
19 schema:description In the United States, the estimated number of new cases of renal cell carcinoma (RCC) is approximately 65,000 case with about 15,000 deaths in the year of 2018 (Siegel et al. in CA Cancer J Clin 68(1):7, 2018). RCC as an immunogenic malignancy is supported by many theories and facts which include tumor richness of lymphocytes infiltrate, the occurrence of spontaneous tumor regression, and the proved effect of traditional immunotherapy (Finke et al. in J Immunother 11(1):1–11, 1992), all these factors support the potential therapeutic effect of the novel immunotherapeutic agents in RCC. Historically, complete tumor regression in metastatic RCC is achievable in a minority of patients through traditional immunotherapies such as high-dose interleukin-2 (IL-2) (Fyfe et al. in J Clin Oncol 13(3):688, 1995) and interferon-alfa (IFNa) (Negrier et al. in N Engl J Med 338(18):1272, 1998); however due to the significant rate of toxicities and low efficacy; accordingly the targeted therapy with tyrosine kinase inhibitors (TKIs) and vascular endothelial growth factor-antibodies (VEGF) became the standard and prevalent treatment approach for advanced RCC both in front and subsequent lines of therapy (Escudier et al. in Ann Oncol. 25(Suppl 3):iii49–iii56, 2014). A new avenue of immunotherapy utilizing novel strategy to block immune checkpoints has emerged in a new era for RCC treatment (Ascierto et al. in J Transl Med 12:291, 2014). Results from clinical trials are encouraging in both front-line and second-line settings, in a phase III trial (CheckMate 025) nivolumab compared to everolimus improved overall survival in previously treated metastatic RCC who had progressed on prior treatment with targeting agents (Motzer et al. in N Engl J Med 373:1803, 2015). CheckMate 214, a phase III trial, demonstrated superior overall survival and objective response with combined checkpoint inhibitors compared to sunitinib in Treatment-Naïve Advanced RCC among intermediate- and poor-risk group (Motzer et al. in N Engl J Med. 378(14):1277–1290, 2018). In this review, we discuss the systemic Immunotherapy with checkpoint inhibitors that have been approved or are currently being investigated in RCC, clinical experience with these agents, and its future development.
20 schema:genre article
21 schema:isAccessibleForFree false
22 schema:isPartOf N1279bd3f18e747a0abcc8418fbd19c16
23 Ncca4af74285c4dc1afd49e0dc661f658
24 sg:journal.1094524
25 schema:keywords CheckMate 214
26 III trials
27 RCC treatment
28 United States
29 advanced renal cell carcinoma
30 agents
31 approach
32 avenues
33 carcinoma
34 carcinoma treatment
35 cases
36 cell carcinoma
37 checkpoint
38 checkpoint inhibitors
39 clinical experience
40 clinical trials
41 complete tumor regression
42 death
43 development
44 effect
45 efficacy
46 endothelial growth
47 era
48 experience
49 fact
50 factors
51 future development
52 group
53 growth
54 high-dose interleukin-2
55 immune checkpoints
56 immunogenic malignancies
57 immunotherapeutic agents
58 immunotherapy
59 improved overall survival
60 inhibitors
61 interferon alfa
62 interleukin-2
63 kinase inhibitors
64 lines
65 low efficacy
66 lymphocytes
67 malignancy
68 metastatic renal cell carcinoma
69 minority
70 minority of patients
71 new avenues
72 new cases
73 new era
74 nivolumab
75 novel immunotherapeutic agents
76 novel strategy
77 number
78 objective response
79 occurrence
80 overall survival
81 patients
82 phase III trials
83 point
84 poor-risk group
85 potential therapeutic effects
86 prevalent treatment approach
87 prior treatment
88 proved effect
89 rate
90 regression
91 renal cell carcinoma
92 renal cell carcinoma treatment
93 response
94 results
95 review
96 richness
97 second-line setting
98 setting
99 significant rate
100 spontaneous tumor regression
101 state
102 strategies
103 subsequent lines
104 superior overall survival
105 survival
106 systemic immunotherapy
107 targeted therapy
108 theory
109 therapeutic effect
110 therapy
111 toxicity
112 traditional immunotherapy
113 treatment
114 treatment approaches
115 trials
116 tumor regression
117 tyrosine kinase inhibitors
118 vascular endothelial growth
119 years
120 schema:name Check point inhibitors a new era in renal cell carcinoma treatment
121 schema:pagination 85
122 schema:productId N1127b5474fb34c5ebf00ed3d083e5810
123 N61d7fcc284f44baba2356db714e872ee
124 Nc4da1a2278a54a3dabe6c9048f7830e9
125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103813735
126 https://doi.org/10.1007/s12032-018-1147-y
127 schema:sdDatePublished 2022-08-04T17:06
128 schema:sdLicense https://scigraph.springernature.com/explorer/license/
129 schema:sdPublisher N5a95f9c024b949bf964561b1e9425244
130 schema:url https://doi.org/10.1007/s12032-018-1147-y
131 sgo:license sg:explorer/license/
132 sgo:sdDataset articles
133 rdf:type schema:ScholarlyArticle
134 N1127b5474fb34c5ebf00ed3d083e5810 schema:name doi
135 schema:value 10.1007/s12032-018-1147-y
136 rdf:type schema:PropertyValue
137 N1279bd3f18e747a0abcc8418fbd19c16 schema:volumeNumber 35
138 rdf:type schema:PublicationVolume
139 N14a5b6ab275f4be184e08591e7fc963b rdf:first sg:person.011543016727.10
140 rdf:rest rdf:nil
141 N25bdcb6ab14f42039755574a0a66bbe3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Antibodies, Monoclonal, Humanized
143 rdf:type schema:DefinedTerm
144 N4478bc84beb2477eb93cd799464fa148 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Humans
146 rdf:type schema:DefinedTerm
147 N5291099b6f434e0cadc0c7b4d0ad0578 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Kidney Neoplasms
149 rdf:type schema:DefinedTerm
150 N5a95f9c024b949bf964561b1e9425244 schema:name Springer Nature - SN SciGraph project
151 rdf:type schema:Organization
152 N5dda0171ce564ad3ab336b67ae8b290e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Antineoplastic Agents, Immunological
154 rdf:type schema:DefinedTerm
155 N61d7fcc284f44baba2356db714e872ee schema:name dimensions_id
156 schema:value pub.1103813735
157 rdf:type schema:PropertyValue
158 N745a8202b60043d6856ca4558ce7d000 rdf:first sg:person.01037220762.97
159 rdf:rest N14a5b6ab275f4be184e08591e7fc963b
160 N8604732003da4566a8df0017deb393b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Programmed Cell Death 1 Receptor
162 rdf:type schema:DefinedTerm
163 N9ed459eb3b304a93b193a7e87d646a8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Nivolumab
165 rdf:type schema:DefinedTerm
166 Nc4da1a2278a54a3dabe6c9048f7830e9 schema:name pubmed_id
167 schema:value 29728867
168 rdf:type schema:PropertyValue
169 Ncca4af74285c4dc1afd49e0dc661f658 schema:issueNumber 6
170 rdf:type schema:PublicationIssue
171 Nd85f3d06c8e54f39971bb58bed17b8b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name B7-H1 Antigen
173 rdf:type schema:DefinedTerm
174 Ne09769bfb4094951bfd8bc619629e9f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Carcinoma, Renal Cell
176 rdf:type schema:DefinedTerm
177 Nf5153361926044a9bfd6e0277b20eb4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Antibodies, Monoclonal
179 rdf:type schema:DefinedTerm
180 Nf5bd4872ab8e434493c9e13f808c4ee5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Randomized Controlled Trials as Topic
182 rdf:type schema:DefinedTerm
183 Nfedc882152244a63adbd9d9705193206 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Ipilimumab
185 rdf:type schema:DefinedTerm
186 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
187 schema:name Medical and Health Sciences
188 rdf:type schema:DefinedTerm
189 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
190 schema:name Oncology and Carcinogenesis
191 rdf:type schema:DefinedTerm
192 sg:journal.1094524 schema:issn 1357-0560
193 1559-131X
194 schema:name Medical Oncology
195 schema:publisher Springer Nature
196 rdf:type schema:Periodical
197 sg:person.01037220762.97 schema:affiliation grid-institutes:grid.490061.a
198 schema:familyName Alsharedi
199 schema:givenName Mohamed
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037220762.97
201 rdf:type schema:Person
202 sg:person.011543016727.10 schema:affiliation grid-institutes:grid.259676.9
203 schema:familyName Katz
204 schema:givenName Heather
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011543016727.10
206 rdf:type schema:Person
207 sg:pub.10.1186/2051-1426-3-s2-p353 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044738460
208 https://doi.org/10.1186/2051-1426-3-s2-p353
209 rdf:type schema:CreativeWork
210 sg:pub.10.1186/s12967-014-0291-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008604592
211 https://doi.org/10.1186/s12967-014-0291-1
212 rdf:type schema:CreativeWork
213 grid-institutes:grid.259676.9 schema:alternateName Department of Hematology/Oncology, Joan C. Edwards School of Medicine Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA
214 schema:name Department of Hematology/Oncology, Joan C. Edwards School of Medicine Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA
215 rdf:type schema:Organization
216 grid-institutes:grid.490061.a schema:alternateName Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, 1400 Hal Greer Blvd., 25701, Huntington, WV, USA
217 schema:name Department of Hematology/Oncology, Joan C. Edwards School of Medicine Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA
218 Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, 1400 Hal Greer Blvd., 25701, Huntington, WV, USA
219 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...